Ayla Bioscience Inc is an Innovative Biological Manufacturing Company

founded by the world’s foremost applied and academic mycologists, with over 100+ combined years’ experience by our senior staff in research, development, and production. Ayla is bringing the future of manufacturing to the world today through our proprietary technology, transforming the way food and medicine are produced. Operating on an entirely new paradigm, Ayla has developed the world’s first proprietary Solid-State Fermentation technology, allowing the application of Biological Manufacturing Techniques utilizing the Fifth Kingdom – the Fungi – as our manufacturing partners to produce high-value, high-demand food, and pharmaceutical active ingredient products, using common agricultural materials as our raw material input.

Ayla’s team has already brought numerous products to market, setting the international
quality standards in several product areas that other companies still struggle to match. And they have brought these products to market at lower cost and higher profit margins than ever thought possible. Ayla’s world-class team on the business management side has many years’ experience managing some of the world’s largest food companies and bringing multiple Startup companies to the stock market, helping develop some of the most recognized international companies in business today.

Pharmaceutical Use of Psilocybin: Ayla Bioscience’s wholly owned Psilocybin Division has completed construction on their new facility in Manchester, Jamaica and has begun production of Psilocybin as of October 2022. Utilizing Ayla’s unique technology, Psilocybin can be produced at a significant discount compared to the methods currently employed by other companies. Our proprietary Solid Substrate Fermentation technology allows the production of Psilocybin at a cost of less than 1/100 the cost of synthesizing this compound in a laboratory.

Ayla’s Jamaica production facility is a 38,000 sq ft, FDA cGMP certifiable manufacturing facility, currently being converted for pharmaceutical-grade production, that will start delivering psilocybin products in Q3, 2022. The facility is fully licensed, construction is completed, and it is currently being equipped with the required large-scale production equipment for industrial-scale pharmaceutical production, with an initial production capacity of 3000 kgs per month. Ayla’s R&D in the psilocybin sector will also be performed at this facility, having both staff of in-house analytical chemists and a well-developed strong relationship with the Pharmaceutical Research Group at the University of the West Indies and the North Carolina A&T University.

From day one this facility can supply the demand of the entire Caribbean basin where Psilocybin is currently legal, with future exports planned to the North American and European pharmaceutical industries. With Ayla’s proprietary Psilocybin production technology, market projections indicate Ayla will be able to supply most of the world’s demand for Psilocybin within two years, at a cost no other company can come close to matching.

Current psilocybin production is dominated by chemical synthesis, starting with the compound 4-hydroxy indole. This precursor chemical is very expensive, with a wholesale cost of $250/gram as of August 2022. The highest average efficiency gained through chemical synthesis is 16%, meaning each gram of the starting material results in only 160 mg of pure psilocybin, at a production cost of over $1550 per gram, just for the raw materials alone!

Utilizing Ayla’s technology, Psilocybin is produced at an efficiency of over 75%, using only low-cost agricultural materials as the feedstock. Comparing it directly to today’s synthetic chemical method shows a dramatically reduced production cost of less than 1/100 the cost of the nearest competitor. Ayla’s Jamaica facility has an initial production capacity of more than 30 million Micro-dose capsules per month, which currently sell at the wholesale level for $2/capsule. Since the raw material is the same whether it is sold to pharma for prescription use or direct to consumers for microdosing  – only the packaging changes – Ayla can shift from pharmaceutical raw materials to micro-dose production swiftly and efficiently, at no additional capital expenditure, depending on the demand and profit margin of the various product lines. This ability to pivot product lines quickly allows Ayla to produce products with the greatest demand and the highest profit of any current company in this sector.

Canada consolidated operations to begin Q1 2023; Ayla’s technology will be used in producing raw materials for the dietary supplement, cosmetic and pharmaceutical industries on a large scale at our facility currently under construction in British Columbia, Canada. Starting with a low-cost crop source as our raw material, we are currently ramping up to initially produce fifty tons per month of Medicinal Mushroom raw materials for these industries, with production scheduled to start in Q1, 2023. Drawing upon our CEO’s 20+ years of experience in the dietary supplement industry, Ayla has a rolodex of approximately 1,000 past and current clients in over 60 countries waiting to take these raw materials for their products.

The lead time for medicinal mushroom-based dietary supplement raw materials in the fall and winter of 2021 was six months at a minimum, and usually closer to a one-year.  Before the pandemic, this market sector grew at 25% per year. Since the beginning of the pandemic in 2020, the demand for these materials has been increasing by more than 100% annually, resulting in a worldwide shortage of Medicinal Mushroom Raw Materials for existing product lines in the dietary supplement sector.

Ayla’s Mushroom Consulting Subsidiary: Ayla Bioscience Inc. has aquired Mushroom Consulting LLC, a Nevada registered company that has been designing and building farms all over the world. Mushroom Consulting was started by Ayla’s CEO, Dr. John Holliday, to help startup mushroom farms and existing farms struggling to make a profit. 

Mushroom Consulting is increasingly active, with current projects running in about a dozen countries and is on track to end the year with revenue in excess of $4,000,000 USD.

For Further Information Contact:

John Holliday
CEO, Ayla Bioscience Inc.
Email: john@aylabioscience.com
Telephone: +1 (775) 230-8975

 Ayla Bioscience, Inc. Disclaimer  

Forward-looking statements give our expectations or forecasts of future events. Sometimes these statements will use words such as anticipate, estimate, expect, project, intend, plan, believe, outlook, prognosis, and other similar words. These statements are not intended as guarantees of our future performance and are subject to risks, uncertainties, and other principal factors that could cause our actual performance to be materially different from those we project.  

Our actual results will be different due to the inherent nature of projections and may be better or worse than projected. These forward-looking statements also represent our estimates and assumptions only as of the date that they initially were made. We expressly disclaim a duty to provide updates to any forward-looking statements, and the estimates and assumptions associated with them, to reflect events or circumstances or changes in expectations or the occurrence of anticipated events after the date they were initially made.